Upgrade to SI Premium - Free Trial

Leerink Modestly Positive on Biogen's (BIIB) Hemophilia Spin; Remains Cautious on Rest of Company

May 3, 2016 2:52 PM
Leerink affirms Biogen (Nasdaq: BIIB) with a Market Perform rating and $319 price target following news that the company is ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Spinoffs

Next Articles